Loading…
UTI - Pharma & Healthcare Fund
Disclosed for 41 months, Jan 2014 to Jun 2017. This scheme is no longer reporting.
Portfolio value
₹334 Cr
up ₹1.2 Cr vs Sep 2016
- Stocks held
- 26
- unchanged
- Top 10 weight
- 75.7%
- of the portfolio in its ten largest
- Cash & debt
UTI - Pharma & Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In October 2016 it disclosed 26 stocks worth ₹334 Cr, up ₹1.2 Cr from Sep 2016. Its largest positions were Sun Pharmaceutical Industries Limited (21.5%), Dr. Reddy's Laboratories Limited (11.8%), Cipla Limited (9.3%); the ten largest together made up 75.7% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 85.1% of its equity. Cash and debt stood at 2.4%. Compared with Sep 2016 the fund entered 0 new stocks and exited 0.
Against 230 other Sectoral / Thematic funds
Concentration
96%
Top-10 weight is higher than 96% of peers
Breadth
10%
Holds more stocks than 10% of peers
Cash
32%
Holds more cash than 32% of peers
What these mean: concentration · cash
Holdings in October 2016
Download CSVEvery line the fund disclosed, with the change against Sep 2016. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 21.50% | down 0.12 pts | ₹71.8 Cr | down ₹16 L | Held |
| Dr. Reddy's Laboratories Limited | 11.75% | up 0.86 pts | ₹39.2 Cr | up ₹3 Cr | Added |
| Cipla Limited | 9.34% | down 0.11 pts | ₹31.2 Cr | down ₹27 L | Trimmed |
| Lupin Limited | 8.66% | down 0.02 pts | ₹28.9 Cr | up ₹4 L | Held |
| Aurobindo Pharma Limited | 6.52% | down 0.37 pts | ₹21.8 Cr | down ₹1.2 Cr | Trimmed |
| Divi's Laboratories Limited | 4.97% | down 0.06 pts | ₹16.6 Cr | down ₹14 L | Trimmed |
| Piramal Enterprises Limited | 3.94% | down 0.16 pts | ₹13.2 Cr | down ₹47 L | Trimmed |
| Alkem Laboratories Limited | 3.60% | down 0.08 pts | ₹12 Cr | down ₹22 L | Trimmed |
| Zydus Lifesciences Limited | 2.72% | up 0.22 pts | ₹9.1 Cr | up ₹76 L | Added |
| IPCA Laboratories Limited | 2.67% | up 0.04 pts | ₹8.9 Cr | up ₹15 L | Added |
| Narayana Hrudayalaya Limited | 2.60% | up 0.08 pts | ₹8.7 Cr | up ₹29 L | Added |
| Sun Pharma Advanced Research Company Limited | 2.56% | up 0.25 pts | ₹8.5 Cr | up ₹86 L | Added |
| Biocon Limited | 2.39% | down 2.70 pts | ₹8 Cr | down ₹9 Cr | Trimmed |
| Cash, TREPS & receivables | 2.36% | up 1.63 pts | ₹7.9 Cr | up ₹5.5 Cr | Added |
| Syngene International Limited | 2.23% | up 0.42 pts | ₹7.4 Cr | up ₹1.4 Cr | Added |
| Strides Pharma Science Limited | 1.74% | up 0.06 pts | ₹5.8 Cr | up ₹22 L | Added |
| Pfizer Limited | 1.59% | down 0.09 pts | ₹5.3 Cr | down ₹27 L | Trimmed |
| Sanofi India Limited | 1.53% | up 0.07 pts | ₹5.1 Cr | up ₹26 L | Added |
| Unichem Laboratories Limited | 1.52% | up 0.11 pts | ₹5.1 Cr | up ₹38 L | Added |
| GlaxoSmithKline Pharmaceuticals Limited | 1.11% | up 0.05 pts | ₹3.7 Cr | up ₹16 L | Added |
| Indraprastha Medical Corporation Limited | 1.10% | up 0.11 pts | ₹3.7 Cr | up ₹39 L | Added |
| Natco Pharma Limited | 1.06% | down 0.03 pts | ₹3.5 Cr | down ₹8 L | Trimmed |
| DISHMAN PHARMACEUTICALS & CHEMICALS LTD. | 0.88% | down 0.07 pts | ₹2.9 Cr | down ₹21 L | Trimmed |
| Torrent Pharmaceuticals Limited | 0.60% | down 0.09 pts | ₹2 Cr | down ₹30 L | Trimmed |
| Shilpa Medicare Limited | 0.53% | up 0.05 pts | ₹1.8 Cr | up ₹17 L | Added |
| Indoco Remedies Limited | 0.38% | down 0.04 pts | ₹1.3 Cr | down ₹13 L | Trimmed |
| Thyrocare Technologies Limited | 0.14% | up 0.01 pts | ₹46 L | up ₹2 L | Added |
What changed, Sep 2016 to Oct 2016
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Dr. Reddy's Laboratories Limitedup ₹3 Cr (+0.86% pts)
- Syngene International Limitedup ₹1.4 Cr (+0.42% pts)
- Sun Pharma Advanced Research Company Limitedup ₹86 L (+0.25% pts)
- Zydus Lifesciences Limitedup ₹76 L (+0.22% pts)
- Indraprastha Medical Corporation Limited
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Sep 2016, the weight rose most in Healthcare Services (+0.7 pts) and Pharmaceuticals (+0.1 pts), and fell most in Pharmaceuticals & Biotechnology (−0.8 pts).
- Healthcare Services5.5% → 6.2%+0.7 pts
- Pharmaceuticals4.5% → 4.6%+0.1 pts
- Pharmaceuticals & Biotechnology85.9% → 85.1%−0.8 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Oct 2015 | Apr 2016 | Jul 2016 | Sep 2016 | Oct 2016 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 89.6% | 86.7% | 86.6% | 85.9% | 85.1% |
| Healthcare Services | 2.4% | 5.1% | 5.1% | 5.5% | 6.2% |
| Pharmaceuticals | 5.2% | 4.7% | 4.6% | 4.5% | 4.6% |
| Finance | 2.7% | 3.6% | 3.7% | 4.1% | 4.0% |
Allocation in Oct 2016change vs Sep 2016
- Pharmaceuticals & Biotechnology (17)85.1%▼ 0.8 pts
- Healthcare Services (4)6.2%▲ 0.7 pts
- Pharmaceuticals (4)4.6%▲ 0.1 pts
- Finance (1)4.0%
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Oct 2016
2.4%
▲ 1.6 pts vs Sep 2016
- Cash alone
- 2.4%
- cash and net receivables
- A year earlier
- 9.4%
- Oct 2015 · now ▼ 7.0 pts
- Last 12 months
- 0.7% – 12.6%
- lowest to highest · record 12.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.